Form 4: Immunovant CFO Sells Shares, Acquires Options

Immunovant's Chief Financial Officer, Tiago Girao, reported a transaction involving the sale of 10,000 shares and the acquisition of 10,000 stock options.

Summary

• Tiago Girao, Chief Financial Officer of Immunovant, Inc., engaged in a stock transaction on June 26, 2026.
• Girao sold 10,000 shares of common stock at a weighted average price of $38.46 per share, with individual sale prices ranging from $38.00 to $38.90.
• Following the sale, Girao's beneficial ownership of common stock decreased by 10,000 shares.
• Concurrently, Girao acquired 10,000 stock options to purchase common stock at an exercise price of $15.90, with an expiration date of May 1, 2035.
• These options were awarded on May 1, 2025, and vest over time, with 25% vesting on April 21, 2026, and the remainder vesting quarterly over three years, contingent on continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While the CFO sold shares, they also acquired a significant number of stock options, suggesting a balanced approach to personal financial management and continued belief in the company's long-term prospects.

Positives

• Acquisition of 10,000 stock options at a favorable exercise price of $15.90, indicating potential future upside for the CFO.
• The stock options have a long expiration date of May 1, 2035, providing a significant time horizon for potential appreciation.
• Vesting schedule for options is structured over several years, aligning with long-term company performance and employee retention.

Negatives

• Sale of 10,000 shares of common stock by the CFO, which could be interpreted as a lack of confidence in immediate short-term stock appreciation.
• The sale occurred at a price significantly higher than the exercise price of the newly acquired options.

Risks

• The filing does not explicitly mention any risks associated with these transactions.
• Potential for negative market perception if the sale is viewed as a signal of insider concerns, despite the option grant.

Future Outlook

The future outlook is not directly addressed in this Form 4 filing, which primarily reports on past transactions. However, the acquisition of stock options by the CFO suggests a belief in the company's future performance and stock appreciation.

Management Comments

• The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard for reporting insider transactions. The sale of shares by a CFO, coupled with the acquisition of stock options, is a common practice to diversify holdings while maintaining alignment with company performance through equity incentives.

Stakeholder Impact

• Shareholders: The sale of shares by the CFO might be viewed with caution, but the acquisition of options could signal confidence in future growth.
• Employees: The vesting schedule of the options aligns with employee retention goals.
• Management: The transaction reflects standard executive compensation and personal financial planning practices.

Next Steps

• The CFO will continue to vest in the acquired stock options over the next three years, subject to continued service.
• The CFO may exercise the vested options if the stock price exceeds the exercise price of $15.90.
• The company's performance will determine the ultimate value of the acquired options.

Key Dates

Keywords

Immunovant, IMVT, Form 4, Insider Trading, Stock Options, Share Sale, Beneficial Ownership, CFO, Tiago Girao, SEC Filing